Abeona's ZEVASKYN approval and a $3.1 million price point are undervalued by the market. Find out why ABEO stock is a Buy.

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Approximately a year after the FDA rejected its previous approval submission, Abeona announced that the agency had approved ZEVASKYN, its autologous cell-based gene therapy for both adult and ...

Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand ...

Treatments are expected to begin in the third quarter of 2025. On April 29, 2025, Abeona announced approval from the U.S. Food and Drug Administration (FDA) for ZEVASKYN as the first and only ...

On April 29, 2025, Abeona announced approval from the U.S. Food and Drug Administration (FDA) for ZEVASKYN as the first and only autologous cell-based gene therapy for the treatment of wounds in ...

Zevaskyn will have a weighted average cost of $3.1 million, according to a presentation from the company last month. Following the FDA approval in late April, the company said they will make Zevaskyn ...

The deal comes two weeks after the company picked up FDA approval for Zevaskyn to treat recessive dystrophic epidermolysis bullosa (RDEB), so it's likely some portion of the cash will be used to ...